ArticleHeliyon2024

Post-marketing safety profile of solriamfetol: A real-world disproportionality analysis using FDA adverse event reporting system (FAERS) database.

Beili He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.